Literature DB >> 19111388

Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.

Alan Coss1, Miriam Tosetto, Edward J Fox, Beata Sapetto-Rebow, Sheeona Gorman, Breandán N Kennedy, Andrew T Lloyd, John M Hyland, Diarmuid P O'Donoghue, Kieran Sheahan, Dermot T Leahy, Hugh E Mulcahy, Jacintha N O'Sullivan.   

Abstract

Topoisomerase IIalpha is a nuclear enzyme that regulates the tertiary structure of DNA. The influence of topoisomerase IIalpha gene (TOP2A) or protein alterations on disease progression and treatment response in colorectal cancer (CRC) is unknown. The study investigated the clinical relevance of topoisomerase IIalpha in CRC using in vivo and in vitro models. Differentially expressed genes in early and late-stage CRC were identified by array comparative genomic hybridization (CGH). Cellular location of gene amplifications was determined by fluorescence in situ hybridization (FISH). Topoisomerase IIalpha levels, proliferation index, and HER2 expression were examined in 228 colorectal tumors by immunohistochemistry. Overexpression of topoisomerase IIalpha in vitro was achieved by liposome-based transfection. Cell growth inhibition and apoptosis were quantified using the crystal violet assay and flow cytometry, respectively, in response to drug treatment. Amplification of TOP2A was identified in 3 (7.7%) tumors using array CGH and confirmed using FISH. At the protein level, topoisomerase IIalpha staining was observed in 157 (69%) tumors, and both staining and intensity levels were associated with an aggressive tumor phenotype (p values 0.04 and 0.005, respectively). Using logistic regression analysis, topoisomerase IIalpha remained significantly associated with advanced tumor stage when corrected for tumor proliferation (p=0.007) and differentiation (p=0.001). No association was identified between topoisomerase IIalpha and HER2. In vitro, overexpression of topoisomerase IIalpha was associated with resistance to irinotecan (p=0.001) and etoposide chemotherapy (p=0.03), an effect mediated by inhibition of apoptosis. Topoisomerase IIalpha overexpression is significantly associated with alterations in tumor behavior and response to drug treatment in CRC. Our results suggest that gene amplification may represent an important mechanism underlying these changes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19111388     DOI: 10.1016/j.canlet.2008.11.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  33 in total

1.  DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner.

Authors:  Xian Hua Gao; Zhi Qi Yu; Chang Zhang; Chen Guang Bai; Jian Ming Zheng; Chuan Gang Fu
Journal:  Int J Colorectal Dis       Date:  2011-11-12       Impact factor: 2.571

2.  Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells.

Authors:  Sudhanshu Sudan; Hp Vasantha Rupasinghe
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

3.  Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.

Authors:  Zhou Zhou; Shi Liu; Meng Zhang; Rui Zhou; Jing Liu; Ying Chang; Qiu Zhao
Journal:  Dig Dis Sci       Date:  2017-08-16       Impact factor: 3.199

4.  Expression of Topoisomerase II-α protein in salivary gland tumors.

Authors:  Asaf Shvero; Ohad Hilly; Golan Bubis; Yaniv Hamzany; Rumelia Koren; Lea Rath-Wolfson
Journal:  Mol Clin Oncol       Date:  2017-10-20

5.  Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models.

Authors:  Yan Lu; Pengyuan Liu; Weidong Wen; Clinton J Grubbs; Reid R Townsend; James P Malone; Ronald A Lubet; Ming You
Journal:  Am J Transl Res       Date:  2010-09-20       Impact factor: 4.060

6.  Patterns of expression of DNA repair genes and relapse from melanoma.

Authors:  Rosalyn Jewell; Caroline Conway; Angana Mitra; Juliette Randerson-Moor; Samira Lobo; Jérémie Nsengimana; Mark Harland; Maria Marples; Sara Edward; Martin Cook; Barry Powell; Andy Boon; Floor de Kort; Katharine A Parker; Ian A Cree; Jennifer H Barrett; Margaret A Knowles; D Timothy Bishop; Julia Newton-Bishop
Journal:  Clin Cancer Res       Date:  2010-08-12       Impact factor: 12.531

7.  Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.

Authors:  Chandra M Das; Peter E Zage; Pete Taylor; Dolly Aguilera; Johannes E A Wolff; Dean Lee; Vidya Gopalakrishnan
Journal:  Eur J Cancer       Date:  2010-10       Impact factor: 9.162

8.  Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?

Authors:  H Sevim; J F Parkinson; K L McDonald
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-09       Impact factor: 4.553

9.  Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.

Authors:  Ryan M Gobble; Li-Xuan Qin; Elliott R Brill; Christina V Angeles; Stacy Ugras; Rachael B O'Connor; Nicole H Moraco; Penelope L Decarolis; Cristina Antonescu; Samuel Singer
Journal:  Cancer Res       Date:  2011-02-18       Impact factor: 12.701

10.  TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.

Authors:  Meenu Jain; Lisa Zhang; Mei He; Ya-Qin Zhang; Min Shen; Electron Kebebew
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.